Aditxt Inc.

Aditxt, Inc. is a biotechnology company focused on the discovery and development of biopharmaceutical products. Its pipeline includes AditxtScore and FlowSpot for immune profile monitoring, Apoptotic DNA Immunotherapy (ADI-100) for skin grafting, psoriasis, and type-1 diabetes, and Pearsanta for molecular tests based on mitochondrial DNA for early cancer detection. It also offers Mitomic for detecting mitochondrial DNA mutations, Adivir for infectious disease, and Adifem for women's health. The company has license agreements with Loma Linda University and Leland Stanford Junior University. Formerly known as ADiTx Therapeutics, Inc., it changed its name to Aditxt, Inc. in July 2021, was incorporated in 2017, and is headquartered in Mountain View, California.